

MONDAY, NOVEMBER 18, 2019

1:00 PM TO 1:30 PM	CONFERENCE REGISTRATION & NETWORKING SHANGHAI JING AN SHANGRI-LA (3RD FLOOR)
1:30 PM TO 3:30 PM	C-SUITE CLINICAL DEVELOPMENT BOOTCAMP (INCLUDED IN CONFERENCE REGISTRATION) MAGNOLIA BALLROOM 1 (3RD FLOOR) Success in finding strategic partners and winning regulatory approval hinges on crucial product development decisions, beginning at discovery. The hurdles are becoming even more complicated as regulators are quickly adopting new endpoints, clinical designs and new statistics to address today's complex new products. This session is especially tailored for Chinese executives who are responsible for make-or-break decisions years before their product ever reach the patient. The Bootcamp is divided into three parts: Regulatory, Early Development and Clinical Operations. Session Chair: • LingJi Shi, Ph.D., Founder & CEO, dMed Biopharmaceutical Co. Ltd. Featuring: • Wenyu GUO, M.D., VP, Clinical Operations, CStone Pharmaceuticals Co. Ltd. • Min Irwin, Ph.D., CEO, Reistone Biopharma Co. Ltd. • Helen Qinghong Li, M.D., Head, Medical Quality Assurance, China, Pfizer Inc. • Yi LIU, VP, Clinical Science & Medical Affairs, dMed Biopharmaceutical Co. Ltd. • Chris Lu, Ph.D., Founder & CEO, Laekna Therapeutics Shanghai Co. Ltd. • Joan Shen, M.D., CEO, Hatab Biopharma Co. Ltd. • Jun Shi, M.D., SVP, Early Development & Clinical Pharmacology, dMed Biopharmaceutical Co. Ltd. • Angela Yan, SVP, Regulatory Affairs & Strategy, dMed Biopharmaceutical Co. Ltd. • Peiyang YAO, Executive Director, Quality Assurance, dMed Biopharmaceutical Co. Ltd. • Eric Zhang, Ph.D., VP, Regulatory Affairs & Strategy, dMed Biopharmaceutical Co. Ltd.
3:30 PM TO 4:00 PM	NETWORKING BREAK SHANGHAI JING AN SHANGRI-LA
4:00 PM TO 6:00 PM	C-SUITE COMMUNICATIONS BOOTCAMP (INCLUDED IN CONFERENCE REGISTRATION) MAGNOLIA BALLROOM 1 (3RD FLOOR) Beyond geopolitics, Chinese biopharma executives share a common challenge with their peers inside the U.S.: How to deal with unrelenting demands for information, transparency and access to investors, regulators, partners, the public and the media. This session is especially tailored for Chinese executives who must successfully communicate with all these stakeholders in order to become global players. Hosted by Brunswick Group, Sidley & Austin LLP, BioCentury and BayHelix Session Chairs: • Ruchun Ji, Partner, Sidley Austin LLP • ZHOUI Yi, Director, Brunswick Group LLP Featuring: • Karen Bernstein, Ph.D., Chairman, BioCentury Inc. • Lanthe Chen, Ph.D., Senior Counselor, Brunswick LLP • Meng DING, Partner, Sidley Austin LLP • Vijay Karwal, Head of Healthcare Investment Banking, Asia ex-Japan, Nomura • Derrick Li, Head of Strategy & Investor Relations, Cellular Biomedicine Group • Judith Li, Partner, Lilly Asia Ventures • Joseph Chi Lo, Partner, Brunswick Group LLP • St John Moore, Partner & Head of Beijing, Brunswick Group LLP • Dongxu QIU, Ph.D., Co-Founder & Executive VP, Strategy and Business Development, CanSino Biologics Inc.
6:00 PM TO 9:00 PM	WELCOME RECEPTION SHANGHAI JING AN SHANGRI-LA, LIFESTYLE SUITE & GARDEN (4TH FLOOR) Network with biotech C-suite executives and investors from China, Asia and the West. Hosted by Pivotal China BioVenture, Nan Fung Life Sciences, BioCentury and BayHelix

TUESDAY, NOVEMBER 19, 2019

7:45 AM TO 8:50 AM	CONFERENCE REGISTRATION & BREAKFAST NETWORKING SHANGHAI JING AN SHANGRI-LA (5TH FLOOR) Hosted by CEC Capital, BioCentury and BayHelix		
8:50 AM TO 9:00 AM	WELCOMING REMARKS • David Flores, President & CEO, BioCentury • Victor Shi, Ph.D., Chairman, BayHelix, and CEO, Adicon Clinical Laboratories Inc.		
9:00 AM TO 9:50 AM	BLUE RIBBON PANEL: CHINA IN THE WORLD BALLROOM 1 (5TH FLOOR) To provide context for the entire conference, BioCentury and BayHelix convene a special Blue Ribbon Panel to debate the challenges China must address to stand alongside the world's leaders in the innovation ecosystem. Session Chairs: • Karen Bernstein, Ph.D., Chairman, BioCentury Inc. • Victor Shi, Ph.D., Chairman, BayHelix, and CEO, Adicon Clinical Laboratories Inc. Featuring: • LI CHEN, Ph.D., Founder & CEO, Hua Medicine Ltd. • Joe Diamond, EVP, International Affairs, BIO (Biotechnology Innovation Organization) • Tao FU, President & Chief Operating Officer, Zai Lab Ltd. • James Mendenhall, Partner, Sidley Austin LLP and former General Counsel, Office of the United States Trade Representative • Graziano Seghezzi, Managing Partner, Sofinova Partners • Xiaobin WU, Ph.D., General Manager, China & President, BeiGene Ltd.		
9:50 AM TO 10:20 AM	FIRESIDE CHAT – IP REFORMS IN CHINA BALLROOM 1 (5TH FLOOR) Intellectual property rules like patent linkage and data exclusivity have been pivotal to the growth of biotechnology in the West. But China's blueprint for IP reform remains stalled. In this rare discussion, the former chief judge of the U.S. patent court and the former senior judge of the IP Division of the Beijing People's Court describe how unlocking these reforms will enable China's innovators to compete on a level playing field with their Western peers. Moderator: • Tony Chen, Partner, Jones Day Featuring: • Yongshun CHENG, Director, Beijing Intellectual Property Institute, and former Senior Judge, IP Division, Beijing High People's Court • Randall Rader, Principal, The Rader Group, and former Chief Judge, U.S. Court of Appeals for the Federal Circuit		
10:20 AM TO 10:50 AM	MORNING NETWORKING BREAK Hosted by CEC Capital, BioCentury and BayHelix		
10:30 AM TO 12:30 PM	PRESENTING COMPANIES: CHINA BIOTECH TRACK (SESSION 1) BALLROOM 2 (5TH FLOOR) Hosted by BeiGene Ltd., BioCentury and BayHelix 10:30am-10:45am BeiGene Ltd. (NASDAQ:BGNE; HKEX:6160) 10:45-11am Hua Medicine Ltd. (HKSE:2552) 11am-11:15am Transcanta Holding Ltd. 11:15am-11:30am EOC Pharma Group 11:30am-11:45am Impact Therapeutics Inc. 11:45am-12pm Yisheng Biopharma Co. Ltd. 12pm-12:15pm Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. 12:15pm-12:30pm AffaMed Therapeutics		
10:50 AM TO 11:40 AM	4TH ANNUAL CSO/CMO ROUNDTABLE BALLROOM 1 (5TH FLOOR) The Summit's 4th Annual Heads of Research Roundtable is expanding this year to include CMOs, as we analyze how far China's R&D leaders and scientist-CEOs have come along the innovation pathway, and what challenges they must conquer – from science to talent to clinical development – to enable their companies to stand alongside the world's leaders in the creation of novel products that address profound patient needs. Session Chair: • Steve Yang, Ph.D., EVP, Chief Business Officer, WuXi AppTec Featuring: • Yong Ben, M.D., Chief Medical Officer, Immuno-Oncology, BeiGene Ltd. • Hongtao LU, Ph.D., Co-Founder, Chief Scientific Officer & Director, Elipiscience Biopharmaceuticals Co. Ltd. • Sophie Yan, Managing Director, Innovation Hub China & VP, Strategy and Transformation, China, Merck Holding (China) Co. Ltd. • Zaiqiang XING, Ph.D., Founder & CEO, ImxMed Shanghai • Lei XIAO, Ph.D., Chairman, CEO & Chief Scientific Officer, Innovative Cellular Therapeutics Co. Ltd.		
10:50 AM TO 11:30 AM	3RD ANNUAL HEALTHCARE AI/PRECISION MEDICINE SHOWCASE (PART 1) – WHERE DIGITAL HEALTH MEETS PERSONALIZED MEDICINE BALLROOM 3 (5TH FLOOR) Precision medicine arguably won't be realized without advances in the areas of digital health that most directly affect patients – digital therapeutics, digital diagnostics and digital disease management tools. First movers and early adopters include U.S. FDA, multinational pharma and venture-backed innovator start-ups. But it is still early days. Can China leverage its prowess in AI and machine learning to lead in the effort to create digital health products globally? Session Chair: • Simone Fishburn, Ph.D., VP & Editor in Chief, BioCentury Featuring: • Yuzhong CHEN, M.D., Chief Medical Officer & VP, Airdoc • Yiming HAO, General Manager, Innovativ Commercialization Solutions, HLT • Irene Hong, Founding Partner, CEC Capital • Tony Zhang, Founder & CEO, LinkDoc Technology (Beijing) Co. • Hao ZOU, Ph.D., CEO, Tsimage Technology, and Director, Center for Medical Imaging and Health, Tsinghua University		
11:30 AM TO 12:10 PM	3RD ANNUAL HEALTHCARE AI/PRECISION MEDICINE SHOWCASE (PART 2) – DRUG DISCOVERY BALLROOM 3 (5TH FLOOR) Artificial intelligence is rapidly propagating into drug discovery. In this third year of the AI/Precision Medicine Showcase, the panel of data scientists reviews what has China accomplished in AI and machine-learning that will affect the speed and effectiveness of the global discovery engine, and identify the next frontiers at the intersection of data and biology. Session Chair: • Weyli ZHANG, Director, External Innovation China, Boehringer Ingelheim GmbH Featuring: • Hongming CHEN, Ph.D., Professor & Principal Investigator, Guangzhou Regenerative Medicine and Health, Guangdong Laboratory (GRM-H-GDL) • Tao GUO, Ph.D., VP & Head, International Discovery Service Unit, WuXi AppTec • Guido Lanza, President & CEO, Numerate Inc. • Pek Lum, Ph.D., CEO, Auransa Inc. • Alex Zhavoronkov, Ph.D., CEO, Insilico Medicine Inc.		
11:40 AM TO 12:20 PM	SCALING UP CHINA BALLROOM 1 (5TH FLOOR) Biotech's history is clear: It's been easy to start companies. The challenge is to build sustainable businesses. China has created a small group of belweeners. The question is, what is their path forward? And what are the options for new start-ups that will follow them and build out the ecosystem? Have the winners in the West created the template to follow, or are there new China-centric approaches to business-building that will create bigger successes, faster? Session Chair: • Debra Yu, M.D., President & Chief Business Officer, LianBio Featuring: • Ronnie Ede, CFO, Innovent Biologics Inc. • Nisa Leung, Managing Partner, Qiming Ventures • Bin Li, Ph.D., CEO & Chief Investment Officer, Lake Bio Capital • Jonathan Yining Zhao, Ph.D., Executive Chairman, Transcanta Holding Ltd. • Zhenping ZHU, Ph.D., President of R&D and Chief Scientific Officer, 3SBio Inc.		
12:10 PM TO 1:10 AM	BOXED LUNCH & NETWORKING Grab a boxed lunch and network with China Summit delegates.		
1:00 PM TO 2:00 PM	<table><tr><td>PRESENTING COMPANIES: BELGIUM BIOTECH TRACK (SESSION 2) BALLROOM 2 (5TH FLOOR) Hosted by AGIO Capital and Business Solutions, Flinders Investment and Trade, AWEX, BioCentury and BayHelix 1:00pm-1:15pm Oclimet Oncology N.V. 1:15pm-1:30pm eTherNA immunotherapies N.V. 1:30pm-1:45pm Miracor Medical S.A. 1:45pm-2:00pm Mithra Pharmaceuticals S.A. (Euronext:MITRA)</td><td>PRESENTING COMPANIES: 3RD ANNUAL HEALTHCARE AI/PRECISION MEDICINE SHOWCASE (PART 3) BALLROOM 3 (5TH FLOOR) Hosted by Insilico Medicine Inc., BioCentury and BayHelix 1pm-1:15pm Insilico Medicine Inc. 1:15pm-1:30pm LinkDoc Technology Ltd. 1:30pm-1:45pm Auransa Inc. 1:45pm-2:00pm Happy Life Tech</td></tr></table>	PRESENTING COMPANIES: BELGIUM BIOTECH TRACK (SESSION 2) BALLROOM 2 (5TH FLOOR) Hosted by AGIO Capital and Business Solutions, Flinders Investment and Trade, AWEX, BioCentury and BayHelix 1:00pm-1:15pm Oclimet Oncology N.V. 1:15pm-1:30pm eTherNA immunotherapies N.V. 1:30pm-1:45pm Miracor Medical S.A. 1:45pm-2:00pm Mithra Pharmaceuticals S.A. (Euronext:MITRA)	PRESENTING COMPANIES: 3RD ANNUAL HEALTHCARE AI/PRECISION MEDICINE SHOWCASE (PART 3) BALLROOM 3 (5TH FLOOR) Hosted by Insilico Medicine Inc., BioCentury and BayHelix 1pm-1:15pm Insilico Medicine Inc. 1:15pm-1:30pm LinkDoc Technology Ltd. 1:30pm-1:45pm Auransa Inc. 1:45pm-2:00pm Happy Life Tech
PRESENTING COMPANIES: BELGIUM BIOTECH TRACK (SESSION 2) BALLROOM 2 (5TH FLOOR) Hosted by AGIO Capital and Business Solutions, Flinders Investment and Trade, AWEX, BioCentury and BayHelix 1:00pm-1:15pm Oclimet Oncology N.V. 1:15pm-1:30pm eTherNA immunotherapies N.V. 1:30pm-1:45pm Miracor Medical S.A. 1:45pm-2:00pm Mithra Pharmaceuticals S.A. (Euronext:MITRA)	PRESENTING COMPANIES: 3RD ANNUAL HEALTHCARE AI/PRECISION MEDICINE SHOWCASE (PART 3) BALLROOM 3 (5TH FLOOR) Hosted by Insilico Medicine Inc., BioCentury and BayHelix 1pm-1:15pm Insilico Medicine Inc. 1:15pm-1:30pm LinkDoc Technology Ltd. 1:30pm-1:45pm Auransa Inc. 1:45pm-2:00pm Happy Life Tech		
1:10 PM TO 2:00 PM	HARD DECISIONS FOR ONCOLOGY DRUG DEVELOPERS BALLROOM 1 (5TH FLOOR) Cancer is the great magnet for biopharma company formation and finance. But the results could be disappointing. Oncology drugs fight for smaller and smaller patient populations and their share of profit will be diminished by molecular diagnostics and combination therapies that will also demand a share of the market. What are the key decisions that oncology drug developers must make to succeed? And will Chinese companies be exempt from this reality? Session Chair: • Simone Fishburn, Ph.D., VP & Editor in Chief, BioCentury Featuring: • Laura Benjamin, Ph.D., President & CEO, Oncopelt Inc. • Thomas Dubensky, Ph.D., President & CEO, Tempest Therapeutics Inc. • Frank Jiang, M.D., Ph.D., Chairman & CEO, CStone Pharmaceuticals Co. Ltd. • Lewis T. "Rusty" Williams, M.D., Ph.D., CEO, Waking Fish Therapeutics, and Venture Partner, Quan Capital • Danjun Yang, M.D., Ph.D., Chairman & CEO, Ascentage Pharma • Frank Zhang, Ph.D., CEO, GenScript Biotech Corp., and Chairman, Legend Biotech		
2:00 PM TO 2:40 PM	THE HOT SPOT RACE BALLROOM 1 (5TH FLOOR) While scientific prowess is distributed throughout the U.S. and Europe, only a few locations have attracted a critical mass of talent. Where will the hot spots of biopharma rise outside of Shanghai, Beijing and Suzhou? Session Chair: • Stella Xu, Ph.D., Managing Director, Quan Capital Featuring: • Kewen JIN, M.D., Managing Partner, Serica Partners • Jin Li, Ph.D., Chairman & CEO, HiGen Ltd. • Andrew Wong, VP, Transactions Asia Pacific, Johnson & Johnson Innovation • Tina Xu, VP, China Digital & Commercial Innovation, AstraZeneca Plc • Guo-Liang Yu, Ph.D., CEO & Co-founder, Apollomics Inc.		
2:05 PM TO 3:20 PM	PRESENTING COMPANIES: U.K. BIOTECH TRACK (SESSION 3) BALLROOM 2 (5TH FLOOR) Hosted by BIA 2:05pm-2:20pm Vaccitech Ltd. 2:20pm-2:35pm Crescendo Biologics Ltd. 2:35pm-2:50pm Oxford Biomedica plc (LSE:OXB) 2:50pm-3:05pm Arecor Ltd. 3:05pm-3:20pm LightOx Ltd.		
2:40 PM TO 3:20 PM	HOW TO SOLVE CHINA'S TALENT CHALLENGES BALLROOM 1 (5TH FLOOR) The shortage of top management talent is a worldwide problem, including in the U.S. To be a top player in the global ecosystem, China must not only find scarce executive leadership, but also build skills that meet global requirements for excellence in product discovery and development. How can China become a destination for the talent it needs, or can it find a different management model that leverages the best people wherever they may be? Session Chair: • Peter Zhang, Executive Director, Russell Reynolds Associates Featuring: • Jun Bao, Ph.D., CEO, Impact Therapeutics Inc. • James Huang, Managing Partner, KPOB China, and Founding Managing Partner, Panacea Venture • Liping LIU, Ph.D., Founder, CEO & Chief Scientific Officer, HighTide Therapeutics Inc. • Pony Liu, CEO, Vison Pharmaceuticals • Gary Wang, VP, Human Resources, APAC & Co-Lead Global HR, BeiGene Ltd.		
3:20 PM TO 3:50 PM	AFTERNOON NETWORKING BREAK		
3:30 PM TO 6:00 PM	PRESENTING COMPANIES: GLOBAL BIOTECH TRACK 1 (SESSION 4) BALLROOM 2 (5TH FLOOR) Hosted by Zai Lab Ltd., BioCentury and BayHelix 3:30pm-3:45pm Zai Lab Ltd. (NASDAQ:ZLAB) 3:45pm-4pm Synaffix B.V. 4pm-4:15pm Oncologie Inc. 4:15pm-4:30pm Hookipa Pharma Inc. (NASDAQ:HOOK) 4:30pm-4:45pm Boston Pharmaceuticals Inc. 4:45pm-5pm Traction Pharmaceuticals Inc. (NASDAQ:TCON) 5pm-5:15pm Bioshin subsidiary of Bioshin Pharmaceutical Holding Co. Ltd. (NYSE:BHVN) 5:15pm-5:30pm Genenta Science s.r.l. 5:30pm-5:45pm CytomX Therapeutics Inc. (NASDAQ:CTMX) 5:45pm-6pm Sotio a.s.		
3:50 PM TO 4:30 PM	THE MANUFACTURING ROAD BALLROOM 1 (5TH FLOOR) For China to stand alongside the world's leaders in biopharma innovation, it requires local manufacturing that meets global standards and delivers affordably at scale. China's new Marketing Authorization Holder policy could create a level playing field for Chinese innovators to access manufacturers like Western biotechs. What remains to be answered is how China will create a global brand in quality that will stimulate demand for its first-generation biologics and help validate its next-generation of manufacturing innovators in new modalities like cell therapy. Session Chair: • Dianna Qian, Partner, Pivotal BioVenture China Featuring: • Carl Firth, Ph.D., Founder & CEO, Asian Pharmaceuticals Ltd. • Wei KANG, VP, Strategic Consulting, AUSTAR Group • Wei Rhee, Ph.D., CEO, SCM Life Sciences, and Chairman, Council for Advanced Regenerative Medicine • Kristine Shen, VP, Global Business Development & Key Account Management, Boehringer Ingelheim Biopharmaceuticals GmbH • Yongzhong WANG, Ph.D., CEO, CMAB BioPharma Ltd.		
4:30 PM TO 5:20 PM	CROSS BORDER STRATEGIES FOR CHINA/EUROPE PARTNERSHIPS BALLROOM 1 (5TH FLOOR) China investors have discovered the promise of European innovation, while Europe's innovators have discovered the opportunities to develop drugs and diagnostics in China. But how does each side find the right partners? Session Chairs: • Sean Cao, Ph.D., CEO, Everest Medicines Ltd. • Henk Joos, Ph.D., General Manager, Agio Capital & Business Solutions Featuring: • David Cox, Ph.D., Director, Healthcare, Panmure Gordon and Co. • Theodora Harold, CEO, Crescendo Biologics Ltd. • Bart Van Hooland, Founding Partner, DROIA Oncology Ventures • Da LIU, Managing Director, CR-CP Life Science Fund • Chengbin Wu, Ph.D., Founder & CEO, Epimab Biopharmaceuticals Inc. • John Zhu, Ph.D., Partner, 6 Dimensions Capital		
6:00 PM TO 10:00 PM	GALA RECEPTION & DINNER BALLROOM 3 (5TH FLOOR) Hosted by CBC Group, BioCentury and BayHelix		

WEDNESDAY, NOVEMBER 20, 2019

7:45 AM TO 8:50 AM	REGISTRATION & BREAKFAST NETWORKING SHANGHAI JING AN SHANGRI-LA (5TH FLOOR) Hosted by Novo Nordisk, BioCentury and BayHelix
8:50 AM TO 9:00 AM	WELCOMING REMARKS • Joshua Berlin, Executive Director, BioCentury
9:00 AM TO 9:40 AM	FIRESIDE CHAT – CHINA INSIDE AND OUT BALLROOM 1 (5TH FLOOR) Luke Meils, President of Global Pharmaceuticals at GlaxoSmithKline Plc., oversees more than \$20 billion in sales in more than 100 markets worldwide. His career has included serving as Executive Vice President of Global Product and Portfolio Strategy, Global Medical Affairs and Corporate Affairs at AstraZeneca plc and as Regional Vice President of Asia Pacific for the Pharmaceuticals Division of Roche. His views on the emergence and future of China provides the context for the second day of the Summit and its focus on "managing for domestic and global impact." Moderator: • Jeff Alkazy, Senior Partner, McKinsey & Co. Featuring: • Luke Meils, President, Global Pharmaceuticals, GlaxoSmithKline Plc.
9:40 AM TO 10:30 AM	THE BRIDGE TO INNOVATION REPORT – CHINA IN THE WORLD BALLROOM 1 (5TH FLOOR) Insights Partner McKinsey & Co. delivers the key findings from its 6th Bridge to Innovation report, created exclusively for the China Healthcare Summit. Session Chair: • Tina Hou, Partner, McKinsey & Co.
10:30 AM TO 11:00 AM	MORNING NETWORKING BREAK Hosted by Novo Nordisk, BioCentury and BayHelix
10:45 AM TO 12:00 PM	PRESENTING COMPANIES: KOREA BIOTECH TRACK (SESSION 5) BALLROOM 2 (5TH FLOOR) Hosted by KDDF (Korea Drug Development Fund), BIP focus, BioCentury and BayHelix 10:45am-11am Isu Abxis Co. Ltd. (KOSDAQ:086899) 11am-11:15am ImmuneOnca Therapeutics Inc. 11:15am-11:30am OilPass Corp. (KOSDAQ:244460) 11:30am-11:45am GeneMedicines Co. Ltd. 11:45am-12pm PharmAbcine Inc. (KOSDAQ:208340)
11:00 AM TO 12:00 PM	VIEW FROM THE TOP – SEEING CHINA IN THE GLOBAL CONTEXT BALLROOM 1 (5TH FLOOR) China is demanding the attention of global biopharma strategists. This panel of biopharma executives, all charged with managing from a global context, reflect on China's growing influence and its implications for APAC, emerging markets and the world beyond. Session Chair: • Martin Dewhurst, Senior Partner & Global Co-Lead, Pharmaceuticals & Medical Products Practice, McKinsey & Co. Featuring: • Alberto Colzi, President International, Japan, Emerging Markets & Australia, AbbVie Inc. • Fabio Landazabal, M.D., SVP & Head of Emerging Markets, GlaxoSmithKline plc • Ai Hua Ong, VP & Regional General Manager, JAPAC, Amgen Inc. • Leon Wang, EVP, International Region & China President, AstraZeneca
12:00 PM TO 1:30 PM	10TH ANNUAL BAYHELIX AWARDS LUNCH BANQUET BALLROOM 3 (5TH FLOOR) For the 10th year, BayHelix celebrates outstanding individuals and companies for achievements and contributions to China's healthcare ecosystem: R&D Achievement of the Year, Deal of the Year, Commercial Achievement of the Year, Company of the Year, and Person of the Year. Emcee: • Victor Shi, Ph.D., Chairman, BayHelix, and CEO, Adicon Clinical Laboratories Inc.
1:30 PM TO 2:30 PM	VIEW FROM THE TOP – CHINA GM PERSPECTIVES BALLROOM 1 (5TH FLOOR) Biopharma businesses in China are at a new crossroads, with innovation taking off and mature brands under the pressure of volume-based purchasing policies. In the Summit's 6th annual GM plenary, China Country presidents share their views on where the market is headed and how they plan to address today's major uncertainties. Session Chair: • Jake Henry, Senior Partner & Global Co-Lead, Pharmaceuticals & Medical Products Practice, McKinsey & Co. Featuring: • Zaiqiang XING, President & General Manager, China, Eli Lilly and Co. • Christian Hogg, Executive Director & CEO, CHiMed (Hutchison China MedTech Ltd.) • Plus S. Hornstein, Ph.D., Country Chair & General Manager, Sanofi China • Joseph Romanelli, President, MSD China
1:30 PM TO 4:00 PM	PRESENTING COMPANIES: GLOBAL BIOTECH TRACK 2 (SESSION 6) BALLROOM 2 (5TH FLOOR) Hosted by Zai Lab Ltd., BioCentury and BayHelix 1:30pm-1:45pm Summit Therapeutics plc (NASDAQ:SMMT) 1:45pm-2pm Tempest Therapeutics Inc. 2:00pm-2:15pm Anima Biotech Inc. 2:15pm-2:30pm Aptorum Group Ltd. (NASDAQ:APM) 2:30pm-2:45pm Retrogenix Ltd. 2:45pm-3:00pm EryDel S.p.A. 3:00-3:15pm DotBio Plc. Ltd. 3:15pm-3:30pm Elipiscience Biopharma Ltd. 3:30pm-3:45pm Bioconotech Therapeutics S.L. 3:45pm-4:00pm Q3 Medical Devices Ltd.
2:30 PM TO 3:20 PM	CAPITAL MARKETS SHOWCASE – FOLLOW THE MONEY BALLROOM 1 (5TH FLOOR) The first great wave of Chinese investor money has joined the biopharma ecosystem in the West, while the first wave of innovator biotechs has tapped the Chinese capital markets. The Summit's 2nd Capital Markets Showcase asks what happens next? Are Chinese fund flows sustainable, and what needs to happen for Hong Kong and Shanghai to become destinations for global fundraisers? Session Chair: • Vijay Karwal, Head of Healthcare Investment Banking, Asia ex-Japan, Nomura Featuring: • Michael Chan, Head, International Issuer Services, Hong Kong Exchanges and Clearing Ltd. • James Lin, Partner, Davis Polk • Xianping LIU, Ph.D., Founder, Chairman & CEO, Shenzhen Chipscreen Biosciences Ltd. • Ning LI, Ph.D., Executive Director, CEO & GM, Shanghai Junshi Biosciences Co. Ltd. • Steven Powell, Ph.D., CEO, eTherNA immunotherapies N.V. • Jinzi WU, Ph.D., Founder, Chairman & CEO, Ascletis Pharma
3:20 PM TO 4:00 PM	CLOSING PLENARY: SPEAKING FOR CHINA'S INNOVATORS BALLROOM 1 (5TH FLOOR) China's biopharma innovators face enormous tasks. They must compete against global competition and communicate to China's policy makers what they need to succeed. SONG Rulin, Executive President of PHIRDA, the China Pharmaceutical Innovation and Research Development Association, and KANG Wei, Managing Director of RDPAC, the R&D-Based Pharmaceutical Association Committee, discuss how their members are addressing these twin challenges in a discussion with Kevin Li of LYZZ Capital. Moderator: • Kevin Li, Ph.D., Co-Founder & Managing Partner, LYZZ Capital Featuring: • Wei KANG, Managing Director, RDPAC (R&D-Based Pharmaceutical Association Committee) • Rulin SONG, Executive President, PHIRDA (China Pharmaceutical Innovation and Research Development Association)
4:00 PM TO 4:30 PM	CLOSING RECEPTION – LAST CALL FOR NETWORKING SHANGHAI JING AN SHANGRI-LA (5TH FLOOR) Join BioCentury, BayHelix and McKinsey & Co. for a final round of networking with China Summit delegates.